Homeostatic Model Assessment (HOMA)

Size: px
Start display at page:

Download "Homeostatic Model Assessment (HOMA)"

Transcription

1 Homeostatic Model Assessment (HOMA) Historically, insulin resistance (IR) was measured with an invasive test called a euglycemic clamp test. Basically it s a test to measure how much insulin a person needs to keep their glucose level constant, despite the addition of glucose. The less insulin one requires, the more insulin sensitive one is. A much simpler way to estimate insulin sensitivity is to use a test called HOmeostasis Model Assessment (HOMA). It is a mathematical model which can estimate an individual's degree of insulin sensitivity (HOMA %S) and level of beta cell function (HOMA %B) from simultaneous measurements of fasting plasma glucose and insulin or C-peptide concentrations. (1) Types of Models Physiological Basis for HOMA Model HOMA models the physiologic glucose/insulin feedback system mathematically. It incorporates data on pancreatic beta-cell function (BCF) plus peripheral (muscle and brain) and hepatic insulin sensitivity as well as glucose and insulin measured in the fasting state. The model estimates an individual's insulin sensitivity based on the assumption that any one combination of glucose and insulin is associated with a given insulin sensitivity, or, conversely, their insulin resistance. (2) Homeostatic Model Assessment (HOMA) 1

2 HOMA1 (1985 Model) versus HOMA2 (1996 Model) In 1985, David Matthews et al published HOMA1. This model, written in Fortran, took greater account of peripheral glucose uptake and could use fasting levels of specific insulin or C-peptide in addition to RIA insulin. (3) HOMA1: The Original HOMA Model Contains a simple mathematical approximation of the original nonlinear solution to the iterative equations; the equations are widely used and simplify to: IR-Insulin resistance; FPI-Fasting plasma insulin; FPG-Fasting plasma glucose; %B-Beta cell function In 1998, Jonathan Levy et al published an updated HOMA model (HOMA2) which took account of variations in hepatic and peripheral glucose resistance, increases in the insulin secretion curve for plasma glucose concentrations above 10 mmol/l (180 mg/dl) and the contribution of circulating proinsulin. The model was recalibrated also to give %B and %S values of 100% in normal young adults when using currently available assays for insulin, specific insulin or C-peptide. (4) HOMA2: The Updated HOMA/ Computer Model Has nonlinear solutions and accounts for variations in hepatic and peripheral glucose resistance. This version incorporates an estimate of proinsulin secretion into the model and thus allows the use of either total (radioimmunoassay) or specific insulin assays. Renal glucose losses have also been included in the model, thus allowing its use in hyperglycemic subjects. HOMA2 has been recalibrated in line with current insulin assays and extended to allow the use of C-peptide if required. In 2004, the HOMA Calculator was released. This provides quick and easy access to the HOMA2 model. Validation of HOMA Model HOMA has been compared with a number of wellvalidated methods used to measure IR and BCF. Although the hyperinsulinemic euglycemic clamp and the hyperglycaemic clamp are often referred to as the gold standard tests, there is no justification for the view that these tests are yielding indexes that Homeostatic Model Assessment (HOMA) 2

3 are superior to HOMA. There is good correlation between estimates of IR derived from HOMA and from the euglycemic clamp and the minimal model. Estimates of BCF using HOMA have been shown to correlate well with estimates using continuous infusion glucose model assessment (CIGMA) (another paradigm model), hyperglycemic clamps, and the acute insulin response from the intravenous glucose tolerance test (IVGTT). Significance of HOMA Model 1. Its simplicity, reproducibility and correspondence to glucose clamp derived estimates of insulin resistance and stimulatory test estimates of insulin secretion has made HOMA a reliable and useful parameter for estimating insulin sensitivity and BCF in both, people with insulin treated (5) and non-insulin treated type 2 diabetes. (1) Clinical Significance of HOMA In diagnosis of 1. Prediabetes 2. Metabolic Syndrome 3. Therapy 2. HOMA assesses changes in BCF and IR in patients with diabetes in order to examine the natural history of diabetes and to assess the effects of treatment. For example, HOMA-IR is a useful predictor of pioglitazone treatment in type 2 diabetic patients (Araki T et al., 2005). In three different 16-week, doubleblind studies, the calculated percentage changes from baseline in insulin resistance and BCF has been summarized in the graphs below: Reduced IR & Improved BCF with Pioglitazone Therapy Compared with baseline, IR significantly decreased in pioglitazone 30 mg, sulfonylurea + pioglitazone 30 mg, and metformin + pioglitazone 30 mg treatment groups by 12.5%, 30.1%, and 18.2% respectively. Whereas, IR increased by 30.3%, 20.1% and 17.6% respectively in placebo, sulfonylurea + placebo, and metformin + placebo treatment groups. Contrarily, significant improvements in BCF was seen in pioglitazone 30 mg, sulfonylurea + pioglitazone 30 mg, and metformin + pioglitazone 30 mg treatment groups with changes of 41.4%, 38.0%, and 37.6% respectively. Compared with baseline, placebo, sulfonylurea + placebo, and metformin + placebo treatment groups also showed improvements in BCF, with changes of 23.4%, 8.2%, and 36.8% respectively. (6) 3. The Mexico City Study propounded that development of diabetes is associated with higher HOMA-IR at baseline. 4. The use of HOMA in normal populations to quantify insulin sensitivity and BCF can be helpful as it allows the collection of longitudinal data in subjects who go on to develop abnormal glucose tolerance. 5. HOMA can be used to track changes in insulin sensitivity and BCF longitudinally in individuals. The model can also be used in individuals to indicate DM=diabetes mellitus; IFG= impaired fasting glucose; IGT= Homeostatic Model Assessment (HOMA) impaired glucose tolerance; NGT= normal glucose tolerance Source: Lin KH et al. Journal of the Chinese Medical 3 Association 74 (2011)

4 whether reduced insulin sensitivity or beta-cell failure predominates. 6. The insulin-glucose-homa-model cannot be used to assess BCF in those taking exogenous insulin. Under such circumstances, the C-peptide-HOMA-model, which uses plasma C-peptide concentrations to reflect endogenous insulin secretion, could be used. (2) 7. According to Verona Diabetes Complications Study, HOMA-IR is an independent predictor of cardiovascular disease (CVD) in type 2 diabetes. The improvement of insulin resistance might have beneficial effects not only on glucose control but also on CVD in patients with type 2 diabetes. (7) Inappropriate Use of HOMA Reporting BCF in Isolation For individuals with normal glucose levels, HOMA solutions might indicate 100% BCF and 100% insulin sensitivity, or, in the case of a thin, fit individual with high sensitivity, 50% BCF and 200% insulin sensitivity. In the latter case, if the beta-cell data are reported in isolation, one might conclude erroneously that the subject had failing beta-cells, as opposed to appropriately low secretion, because the sensitivity of the body was high. A Case In September 2009, Kripa s (name changed) HOMA-IR was 1.38 (ideally it should be 1.00) one sign that she was already insulin resistant. Her fasting glucose was normal (93 mg/dl), and fasting insulin was also normal (6 mu/l). Furthermore, 2 hours after drinking 75 grams of glucose, while her glucose remained normal at 108 mg/dl, her insulin was too high, at 36 mu/l. Hence, both by HOMA- IR and insulin levels, she was clinically insulin resistant, despite never having elevated glucose levels. After making dietary alterations (restriction on sugar intake), Kripa repeated the OGTT and HOMA-IR test in May Her fasting insulin level was undetectable (less than 2 mu/l). Two hours after drinking 75 grams of glucose, her glucose went down from 97 to 83 and insulin spike was only to 16. Her HOMA-IR was now less than Both HOMA-IR and OGTT indicated that she had reversed her insulin resistance with simple dietary changes. Conclusion The HOMA model has proved to be a robust clinical tool in description of the pathophysiology of diabetes. Already quoted in more than 500 publications, it has become one of the standard tools in the armamentarium of clinicians. HOMA analysis allows assessment of inherent BCF and insulin sensitivity and can characterize the pathophysiology in those with abnormal glucose tolerance. Longitudinal data in normal subjects who go on to develop abnormal glucose tolerance is particularly informative. BCF cannot be interpreted in the absence of a measure of insulin sensitivity, and therefore HOMA %S should always be reported alongside HOMA %B. When used appropriately, HOMA can yield valuable data, but as is common with all models, the primary input data need to be robust and the data should be interpreted carefully. Homeostatic Model Assessment (HOMA) 4

5 References 1. R. Holman et al. Diabetologia 2004; 47 (1): A Wallace TM et al. Diabetes Care 2004 ; 27: Matthews DR, et al. Diabetologia 1985; 28: Levy et al. Diabetes Care 1998; 21: Okita K et al. Endocrine Journal 2013; 60 (3): Rosenstock J et al. Diabetologia 2000; 43(1): A Bonora E. Diabetes Care 2002; 25 (7): Tests Offered at SRL Test Name Method Test Code Glucose, Plasma (Fasting) Spectrophotometry 1302H Insulin, Serum (Fasting) Chemiluminescence 3192 C-peptide Chemiluminescence 3140 Homeostatic Model Assessment (HOMA) Spectrophotometry, Chemiluminescence, HOMA Calculator 7561 Register yourself at to get Updates on Recent Trends in Medical Diagnostics Homeostatic Model Assessment (HOMA) 5

Objectives. Introduction

Objectives. Introduction 1 Lab 1: Diabetes Reading 13 th Edition Hole s Diabetes Clinical Application & From Science To Technology (pages 516-517) Table Appendix C (pages 928-930) Objectives 1. To define diabetes mellitus. 2.

More information

Insulin Resistance and Pre-diabetes

Insulin Resistance and Pre-diabetes 1 of 6 11/17/2009 9:38 PM Insulin Resistance and Pre-diabetes What is insulin resistance? What causes insulin resistance? Metabolic Syndrome What is pre-diabetes? What are the symptoms of insulin resistance

More information

Diabetes mellitus. Lecture Outline

Diabetes mellitus. Lecture Outline Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized

More information

Reversing type 2 diabetes: pancreas composition and function during return to normal glucose tolerance

Reversing type 2 diabetes: pancreas composition and function during return to normal glucose tolerance Reversing type 2 diabetes: pancreas composition and function during return to normal glucose tolerance Dr Sarah Steven Clinical Research Fellow to Professor Roy Taylor Observations from bariatric surgery

More information

NOTE: No student will be required to draw his/her own blood.

NOTE: No student will be required to draw his/her own blood. Student Guidelines: Endocrine Physiology Lab CAUTION: Procedures in this exercise involve the use of human blood which puts you at risk of contamination and development of certain life-threatening communicable

More information

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

Clinical Practice Guidelines for Diabetes Management

Clinical Practice Guidelines for Diabetes Management Clinical Practice Guidelines for Diabetes Management Diabetes is a disease in which blood glucose levels are above normal. Over the years, high blood glucose damages nerves and blood vessels, which can

More information

Pathophysiology of Type 2 Diabetes and Its Treatment Policy

Pathophysiology of Type 2 Diabetes and Its Treatment Policy Research and Reviews Pathophysiology of Type 2 Diabetes and Its Treatment Policy JMAJ 53(1): 41 46, 2010 Kohei KAKU* 1 Abstract Impaired insulin secretion and increased insulin resistance, the main pathophysiological

More information

Who typically has Metabolic Syndrome? According to the American Heart Association, three groups of people often have metabolic syndrome:

Who typically has Metabolic Syndrome? According to the American Heart Association, three groups of people often have metabolic syndrome: Metabolic Syndrome By Seth Bilazarian, MD, FACC, FSCAI, RPVI Clinical and Intervential Cardiologist What is the Metabolic Syndrome? The Metabolic Syndrome is a collection of five problems that greatly

More information

Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control. Linda Macdonald, M.D. November 19, 2008

Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control. Linda Macdonald, M.D. November 19, 2008 Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control Linda Macdonald, M.D. November 19, 2008 Objectives Understand the relationship between insulin, carbohydrate intake, and blood

More information

Calculating and Graphing Glucose, Insulin, and GFR HASPI Medical Biology Activity 19c

Calculating and Graphing Glucose, Insulin, and GFR HASPI Medical Biology Activity 19c Calculating and Graphing Glucose, Insulin, and GFR HASPI Medical Biology Activity 19c Name: Period: Date: Part A Background The Pancreas and Insulin The following background information has been provided

More information

BCM 101 BIOCHEMISTRY Week 3 Practical Colorimetric determination of blood sugar level

BCM 101 BIOCHEMISTRY Week 3 Practical Colorimetric determination of blood sugar level BCM 101 BIOCHEMISTRY Week 3 Practical Colorimetric determination of blood sugar level _ In medicine, blood sugar is a term used to refer to the level of glucose in blood. Glucose, transported via the bloodstream,

More information

Diabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO

Diabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children What is Diabetes? How are Diabetes and Obesity

More information

CLINICAL PRACTICE GUIDELINE

CLINICAL PRACTICE GUIDELINE CLINICAL PRACTICE GUIDELINE Procedure: Diabetes Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014 PURPOSE:

More information

Review of Diabetes Therapies: Key Drivers of Disease Progression

Review of Diabetes Therapies: Key Drivers of Disease Progression Review of Diabetes Therapies: Key Drivers of Disease Progression David M. Kendall, MD Medical Director and Chief of Clinical and Professional Services Associate Professor of Medicine University of Minnesota

More information

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME 1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome

More information

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic

More information

Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children

Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children

More information

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D. TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type

More information

Plasma glucose and insulin responses to mixed meals: Impaired fasting glucose re-visited

Plasma glucose and insulin responses to mixed meals: Impaired fasting glucose re-visited 421036DVR8410.1177/1479164111421036Bhat et al.diabetes and Vascular Disease Research Orginal Article Plasma glucose and insulin responses to mixed meals: Impaired fasting glucose re-visited Diabetes &

More information

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference

Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence

More information

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing

More information

Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012

Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes

More information

Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)

Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes

More information

Glucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)

Glucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes

More information

HORMONAL SECRETION OF PANCREAS (PANCREAS 1)

HORMONAL SECRETION OF PANCREAS (PANCREAS 1) HORMONAL SECRETION OF PANCREAS (PANCREAS 1) LEARNING OBJECTIVE: At the end of lecture student should be able to know: What is pancreas. Endocrine and exocrine portion of pancreas, Insulin secretion. Insulin

More information

You are a doctor at a busy general practice surgery in the city suburbs.

You are a doctor at a busy general practice surgery in the city suburbs. You are a doctor at a busy general practice surgery in the city suburbs. Today, four patients who you feel are at risk of diabetes have appointments to discuss the results of recent 'glucose tolerance'

More information

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:

More information

Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement

Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement CLINICALLY T E S T E D Natural Blood Sugar Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Metabolic Syndrome with Prediabetic

More information

DR. Trinh Thi Kim Hue

DR. Trinh Thi Kim Hue TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION

More information

WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible

WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES DEDBT01954 Lilly Deutschland GmbH Werner-Reimers-Straße 2-4 61352 Bad Homburg Living your life as normal as possible www.lilly-pharma.de www.lilly-diabetes.de

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

1. Patient is instructed to eat a normal diet during the days leading up to the test.

1. Patient is instructed to eat a normal diet during the days leading up to the test. Regulation Model 1 The Oral Glucose Tolerance Test (OGTT) is often used to detect diabetes mellitus. The following procedure is used to conduct an OGTT: 1. Patient is instructed to eat a normal diet during

More information

Summary and conclusions. Chapter 8. Summary and conclusions

Summary and conclusions. Chapter 8. Summary and conclusions Summary and conclusions Chapter 8 Summary and conclusions 153 Chapter 8 154 Summary and conclusions Summary This thesis describes an experimental study in healthy MZ and same-sex DZ twins and siblings

More information

Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005

Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005 Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005 Original Article Genetic Association Between Insulin Resistance And Total Cholesterol In Type 2 Diabetes

More information

Assmann Foundation for Prevention 1

Assmann Foundation for Prevention 1 Clinical guidelines usually recommend that the level of high density lipoprotein cholesterol (HDL-C) should be measured. It is frequently argued that HDL-C levels below 35 mg/dl are causally associated

More information

Diabetes in Primary Care course MCQ Answers 2016

Diabetes in Primary Care course MCQ Answers 2016 Diabetes in Primary Care course MCQ Answers 2016 Diagnosis of Diabetes HbA1C should not be used as a diagnostic tool in the following situations: (answer each TRUE or FALSE) 1. Gestational Diabetes TRUE

More information

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening

More information

in Singapore and provide valuable inputs for the the Ministry of Health conducts periodic, population-

in Singapore and provide valuable inputs for the the Ministry of Health conducts periodic, population- 5 Main Report H E A LT H SURVEY Introduction 1 Introduction N AT I O N A L Background The Epidemiology and Disease Control Division of in Singapore and provide valuable inputs for the the Ministry of

More information

Glucose Tolerance Testing

Glucose Tolerance Testing Glucose Tolerance Testing PROTOCOLS FOR PERFORMING GLUCOSE TOLERANCE TESTS INTRODUCTION Described in this section are the sample requirements, patient preparation instructions, dosages of substances to

More information

Reconciling Current Diabetes Guidelines

Reconciling Current Diabetes Guidelines Reconciling Current Diabetes Guidelines Jaime A. Davidson, MD, FACP. FACE Part 1. Diagnosis Welcome. I am Dr. Jaime Davidson, a clinical professor of medicine in the Department of Internal Medicine, Division

More information

Detection of Diabetes Mellitus In Situ (Occult Diabetes) by Joseph R. Kraft, M.D.

Detection of Diabetes Mellitus In Situ (Occult Diabetes) by Joseph R. Kraft, M.D. Detection of Diabetes Mellitus In Situ (Occult Diabetes) by Joseph R. Kraft, M.D. In recent years, further development and refinement of technique has permitted reproducible serum insulin determinations

More information

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc. PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent

More information

Diagnosing Diabetes using HbA1c

Diagnosing Diabetes using HbA1c SUMMARY GUIDELINES FEBRUARY 2013 Diagnosing Diabetes using HbA1c Key messages Aim of the guideline To test for diabetes, use HbA1c instead of fasting plasma glucose or glucose tolerance testing EXCEPT

More information

DIABETES MELLITUS. By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria

DIABETES MELLITUS. By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria DIABETES MELLITUS By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria What is Diabetes Diabetes Mellitus (commonly referred to as diabetes ) is a chronic medical

More information

Introduction. Pathogenesis of type 2 diabetes

Introduction. Pathogenesis of type 2 diabetes Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic

More information

Management of the Athlete with Diabetes Mellitus. Kristin Harmon, M.D. Endocrinologist Tallahassee Primary Care Associates June 8, 2012

Management of the Athlete with Diabetes Mellitus. Kristin Harmon, M.D. Endocrinologist Tallahassee Primary Care Associates June 8, 2012 Management of the Athlete with Diabetes Mellitus Kristin Harmon, M.D. Endocrinologist Tallahassee Primary Care Associates June 8, 2012 Outline Definition of Diabetes Diagnosis Treatment Hypoglycemia and

More information

Metabolic Diseases: Obesity, Hyperlipidemia, and Diabetes

Metabolic Diseases: Obesity, Hyperlipidemia, and Diabetes Metabolic Diseases: Obesity, Hyperlipidemia, and Diabetes Obesity Approximately 1 in 3 adults are overweight in the U.S. Arizona According to CDC, Arizona has highest reported percentage of adults who

More information

INSULIN RESISTANCE IN TYPE 1 DIABETES: DETERMINANTS AND CLINICAL CONSEQUENCES. Christina M. Shay. B.A., John Carroll University, 2001

INSULIN RESISTANCE IN TYPE 1 DIABETES: DETERMINANTS AND CLINICAL CONSEQUENCES. Christina M. Shay. B.A., John Carroll University, 2001 INSULIN RESISTANCE IN TYPE 1 DIABETES: DETERMINANTS AND CLINICAL CONSEQUENCES by Christina M. Shay B.A., John Carroll University, 2001 M.A., Kent State University, 2004 Submitted to the Graduate Faculty

More information

Overdiagnosis and the Epidemic of Pre-Diabetes

Overdiagnosis and the Epidemic of Pre-Diabetes Overdiagnosis and the Epidemic of Pre-Diabetes John S. Yudkin Emeritus Professor of Medicine, University College London Outline The concept of Intermediate Hyperglycaemia - Predicting future diabetes

More information

List of questions. I. General concepts and diagnostic tests

List of questions. I. General concepts and diagnostic tests List of questions I. General concepts and diagnostic tests Diabetes mellitus 2 Glycosylated haemoglobin (HbA1c) 6 Self-monitoring of blood sugar levels 7 How to take an insulin shot 9 Travel tips 10 1.

More information

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS. - Summary

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS. - Summary UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS - Summary CHRONIC COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS - Epidemiological study - PhD Manager: Professor PhD.

More information

Nancy S. Swayze. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, 2000-2001. A. Background

Nancy S. Swayze. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, 2000-2001. A. Background Efficacy Of Insulin Sensitizing Agents In Subjects With Metabolic Syndrome X And Impaired Glucose Tolerance After 6 Months Of Diet And Exercise Therapy Nancy S. Swayze A. Background Impaired glucose tolerance

More information

Update on the management of Type 2 Diabetes

Update on the management of Type 2 Diabetes Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence

More information

Submitted: Feb 09, 2006; Revised: Jun 23, 2006; Accepted: Jun 27, 2006; Published: Jul 08, 2006

Submitted: Feb 09, 2006; Revised: Jun 23, 2006; Accepted: Jun 27, 2006; Published: Jul 08, 2006 Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 5, Issue 1; Jan-Mar 2006 Original Article Comparison of insulin resistance by indirect methods - HOMA, QUICKI and McAuley - with fasting

More information

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational. Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,

More information

The Effect of the Change in the Definition of Type 2 Diabetes on Patient Demographics

The Effect of the Change in the Definition of Type 2 Diabetes on Patient Demographics Int J Endocrinol Metab 2009;2: 51-55 The Effect of the Change in the Definition of Type 2 Diabetes on Patient Demographics ORIGINAL ARTICLE Tildesley HD a,b, Wise JS b, Mazanderani AB a, Aydin CA b, Fraser

More information

Microalbuminuria And Serum Creatinine Levels In Diabetic And Non Diabetic Group A Comparative Study.

Microalbuminuria And Serum Creatinine Levels In Diabetic And Non Diabetic Group A Comparative Study. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 12 Ver. V (Dec. 2015), PP 01-05 www.iosrjournals.org Microalbuminuria And Serum Creatinine

More information

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic

More information

Dr Lee Yin Mei Senior Consultant Gastroenterology NUHS

Dr Lee Yin Mei Senior Consultant Gastroenterology NUHS Dr Lee Yin Mei Senior Consultant Gastroenterology NUHS Simple steatosis (SS), through steatohepatitis Put picture of spectrum Prevalence of NASH 3-25% NASH Progression only occurs in NASH: 27% develop

More information

Department Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage.

Department Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage. Department Of Biochemistry Subject: Diabetes Mellitus Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage. Diabetes mellitus : Type 1 & Type 2 What is diabestes mellitus?

More information

Effect of Exercise on BMI and Biochemical Profile of Selected Obese Diabetic Women

Effect of Exercise on BMI and Biochemical Profile of Selected Obese Diabetic Women Effect of Exercise on BMI and Biochemical Profile of Selected Obese Diabetic Women Nazni, P. *, Poongodi Vijayakumar, T. ** & Angamuthu, K. *** * Lecturer, Department of Food Science, Periyar University,

More information

What is the ideal A1C goal for people with diabetes? a) Under 7% b) 6.5% or less c) 4%- 6%

What is the ideal A1C goal for people with diabetes? a) Under 7% b) 6.5% or less c) 4%- 6% A1C Test Quiz: Are You in the Know About the A1C Test? The dreaded A1C test. Twice or more a year, you have to face this "judge" of all you have done the two or three months before. No matter how hard

More information

Chapter 4 Type 2 Diabetes

Chapter 4 Type 2 Diabetes Chapter 4 Type 2 Diabetes (previously referred to as adult onset diabetes or non-insulin dependent diabetes) H. Peter Chase, MD Cindy Cain, RN, CDE Philip Zeitler, MD This is the most common type of diabetes

More information

ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES

ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES ADJUNCTIVE THERAPIES FOR TYPE 1 DIABETES Dr. Mohammad Alhadj Ali, MD, PgDip, MSc, PhD (UK) with Prof. David Owens (UK) Outline Type 1 Diabetes Immunology of Type 1 Diabetes Treatment of Type 1 Diabetes

More information

Baskets of Care Diabetes Subcommittee

Baskets of Care Diabetes Subcommittee Baskets of Care Diabetes Subcommittee Disclaimer: This background information is not intended to be a comprehensive scientific discussion of the topic, but rather an attempt to provide a baseline level

More information

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust

Insulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2

More information

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:

More information

Phil. J. Internal Medicine, 47: 25-30, Jan.-Feb., 2009

Phil. J. Internal Medicine, 47: 25-30, Jan.-Feb., 2009 Original Articles Pancreatic Insulin Response among Filipino 25 Phil. J. Internal Medicine, 47: 25-3, Jan.-Feb., 29 COMPARISON OF PANCREATIC INSULIN RESPONSE TO GLYCEMIA AMONG FILIPINO SUBJECTS OF VARIOUS

More information

Prediabetes: A Woman s Perspective

Prediabetes: A Woman s Perspective Prediabetes: A Woman s Perspective AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS STATEMENT ON THE DIAGNOSIS AND MANAGEMENT OF PRE-DIABETES IN THE CONTINUUM OF HYPERGLYCEMIA Joanne Kaiser-Smith, D.O., FACOI,

More information

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation

More information

The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies

The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies CLINICAL DIABETES VOL. 18 NO. 2 Spring 2000 PRACTICAL POINTERS The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies Barbara A. Ramlo-Halsted,

More information

PREVALENCE OF TYPE 2 DIABETES MELLITUS IN PATIENTS WITH HEPATITIS C VIRUS INFECTION IN SANA'A, YEMEN.

PREVALENCE OF TYPE 2 DIABETES MELLITUS IN PATIENTS WITH HEPATITIS C VIRUS INFECTION IN SANA'A, YEMEN. PREVALENCE OF TYPE 2 DIABETES MELLITUS IN PATIENTS WITH HEPATITIS C VIRUS INFECTION IN SANA'A, YEMEN. Prepared by: Dr/ Saeed Mana Almaidamah Under supervision of Ass. Prof. Dr/ Mohammed Ba Mashmos IS THERE

More information

Disruption of homeostasis

Disruption of homeostasis Unit 3A Human Form & Function Cells, metabolism & regulation Disruption of homeostasis Read: Study Guide Our Human Species (3 rd edtn) Chapter 12, section 9.3; Chapter 15, section 4.5 Chapter 5, section

More information

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME 1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL SEMINAR INSULIN RESISTANCE, POLYCYSTIC OVARIAN

More information

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,

More information

Diabetes is a. A case for prevention of type 2 diabetes mellitus

Diabetes is a. A case for prevention of type 2 diabetes mellitus A case for prevention of type 2 diabetes mellitus Joseph Cook, DO Diabetes is a disease that has reached epidemic proportions in the United States and around the world. This is troubling because, as bad

More information

A STUDY OF MAGNESIUM SUPPLEMENTATION ON GLYCEMIC CONTROL IN PATIENTS OF TYPE-2 DIABETES MELLITUS

A STUDY OF MAGNESIUM SUPPLEMENTATION ON GLYCEMIC CONTROL IN PATIENTS OF TYPE-2 DIABETES MELLITUS RESEARCH ARTICLE A STUDY OF MAGNESIUM SUPPLEMENTATION ON GLYCEMIC CONTROL IN PATIENTS OF TYPE-2 DIABETES MELLITUS Yogendra Raj Singh 1, Shilpi Verma 2, Dushyant Agrawal 3,*, Brijendra Singh 4, Ashutosh

More information

Chapter 8. Summary and final comments

Chapter 8. Summary and final comments Summary and final comments General introduction The aim of this thesis was to develop and test devices for the continuous in vivo sampling and sensing of glucose and lactate, in clinical monitoring. Currently,

More information

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE

The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step

More information

Diabetes Medications: Insulin Therapy

Diabetes Medications: Insulin Therapy Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta

More information

Jorge Flechas MD, MPH Hendersonville, NC INTRACELLULAR HYPOTHYROIDISM

Jorge Flechas MD, MPH Hendersonville, NC INTRACELLULAR HYPOTHYROIDISM Jorge Flechas MD, MPH Hendersonville, NC 28792 INTRACELLULAR HYPOTHYROIDISM Factors That Affect Thyroid Function Deiodinase 1, 2, 3 and All 3 are Selenium, Zinc Dependent Deiodinase 1 (D1) D1 converts

More information

trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-

trends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223- Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and

More information

Education. Panel. Triglycerides & HDL-C

Education. Panel. Triglycerides & HDL-C Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified

More information

Diabetes, Type 2. RelayClinical Patient Education Sample Topic Diabetes, Type 2. What is type 2 diabetes? How does it occur?

Diabetes, Type 2. RelayClinical Patient Education Sample Topic Diabetes, Type 2. What is type 2 diabetes? How does it occur? What is type 2 diabetes? Type 2 diabetes is a disorder that happens when your body does not make enough insulin or is unable to use its own insulin properly. The inability to use insulin is called insulin

More information

New-Onset Diabetes after Transplantation

New-Onset Diabetes after Transplantation New-Onset Diabetes after Transplantation Dr Mahmoud Darouich Ministry of Health - Damascus The tenth conference of syrian society of nephrology and transplantation Mashta-Alhelou 6-8/11/2008 Cause of Death

More information

Harmony Clinical Trial Medical Media Factsheet

Harmony Clinical Trial Medical Media Factsheet Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual

More information

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?

INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United

More information

Type 2 diabetes is a progressive. status

Type 2 diabetes is a progressive. status Type 2 diabetes is a progressive disease: its treatment the current status Associate Professor Jonathan Shaw Why is type 2 diabetes so hard to treat? How to choose the right glucose-lowering g drug? Page

More information

Diabetes and Obesity. The diabesity epidemic

Diabetes and Obesity. The diabesity epidemic Diabetes and Obesity Frank B. Diamond, Jr. M.D. Professor of Pediatrics University of South Florida College of Medicine The diabesity epidemic Prevalence of diabetes worldwide was over 135 million people

More information

DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES

DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Page 1 DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Drugs to know are: Actrapid HM Humulin R, L, U Penmix SUNALI MEHTA The three principal hormones produced by the pancreas are: Insulin: nutrient metabolism:

More information

vs , P < 0. 01) ( 2B)

vs , P < 0. 01) ( 2B) ( ) J Cent South Univ(Med Sci) 2004,29 (4) 419 C Homa, 3,,, (, 4100011) [ ] : C Homa : 21 (O GTT), 30,60,120 min C C C / ( - 3. 5), Homa ( Homa2IR) ( Homa2islet), Homa (CP) : C : Homa2IR (CP) = 1. 5 +

More information

Diabetic Emergencies. David Hill, D.O.

Diabetic Emergencies. David Hill, D.O. Diabetic Emergencies David Hill, D.O. Class Outline Diabetic emergency/glucometer training Identify the different signs of insulin shock Diabetic coma, and HHNK Participants will understand the treatment

More information

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each

More information

GLUCOSE TOLERANCE (FOR DIABETESMELLITUS)- NON-PREGNANT ADULT/CHILDREN (Under 18 years old) (OGTT)

GLUCOSE TOLERANCE (FOR DIABETESMELLITUS)- NON-PREGNANT ADULT/CHILDREN (Under 18 years old) (OGTT) GLUCOSE TOLERANCE TESTING GESTATIONAL DIABETIC SCREEN (GDS2) GLUCOSE TOLERANCE (FOR DIABETESMELLITUS)- NON-PREGNANT ADULT/CHILDREN (Under 18 years old) (OGTT) GLUCOSE 2-HR POST-GLUCOSE LOAD (2HGPL)-SCREEN

More information

what is diabetes? What actually goes wrong? Talking diabetes No.42

what is diabetes? What actually goes wrong? Talking diabetes No.42 Talking diabetes No.42 what is diabetes? Diabetes is the name given to a group of different conditions in which there is too much glucose in the blood. The pancreas either cannot make insulin or the insulin

More information

Guidelines for the management of hypertension in patients with diabetes mellitus

Guidelines for the management of hypertension in patients with diabetes mellitus Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes

More information

The majority of patients destined to develop

The majority of patients destined to develop RATIONALE FOR DIFFERENT AND EFFECTIVE TREATMENT APPROACHES IN TYPE 2 DIABETES * Martin J. Abrahamson, MD ABSTRACT The most common cause of mortality in diabetes is macrovascular disease, specifically coronary

More information

The National Cholesterol Education Program s Adult

The National Cholesterol Education Program s Adult NHLBI/AHA Conference Proceedings Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition

More information